Although several novel agents are on the horizon, including next-generation tyrosine kinase inhibitors for tertiary mutations ...
1don MSN
Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway
Q3 2025 Management View CEO Alexander Macrae highlighted continued advancement of the clinical and preclinical pipeline, with a focus on managing cash resources. Macrae stated, "In September, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback